공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

뮤코다당증 I형(후를러증후군) : 세계 임상시험 리뷰

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Global Clinical Trials Review, H2, 2017

리서치사 GlobalData
발행일 2017년 12월 상품 코드 303982
페이지 정보 영문 67 Pages
가격
US $ 2,500 ₩ 2,846,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,692,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,538,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


뮤코다당증 I형(후를러증후군) : 세계 임상시험 리뷰 Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Global Clinical Trials Review, H2, 2017
발행일 : 2017년 12월 페이지 정보 : 영문 67 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

뮤코다당증 I형(후를러증후군) 치료제에 관한 임상시험에 대해 조사분석했으며, 임상시험 수 및 피험자수, 단계별 상황, 유망 기업, 개발중인 치료제의 정보, 임상시험 개요 등에 대한 체계적인 정보를 정리하여 전해드립니다.

본 보고서의 개요

각 지역의 임상시험 상황

  • 각국의 임상시험 건수와 평균 피험자수
    • 아시아태평양 지역 주요 5개국의 임상시험 건수
    • 유럽 주요 5개국의 임상시험 건수
    • 북미 주요 국가의 임상시험 건수
    • 중동·아프리카 주요 국가의 임상시험 건수
    • 중남미 주요 국가의 임상시험 건수

G7 국가에서의 임상시험 건수 : 대사이상 치료제 임상시험에서 뮤코다당증 I형(후를러증후군)의 비율

G7 국가의 단계별 임상시험 건수

G7 국가에서의 임상시험 건수 : 진척 상황별

E7 국가에서의 임상시험 건수 : 대사이상 치료제 임상시험에서 뮤코다당증 I형(후를러증후군)의 비율

E7 국가의 단계별 임상시험 건수

단계별 임상시험 건수

  • 진행중인 임상시험 : 단계별

진척 상황별 임상시험 건수

임상시험의 목표 달성 상황

일정기간 채용된 피험자

스폰서 종류별 임상시험 건수

유망 스폰서

뮤코다당증 I형(후를러증후군) 치료제 임상시험에 종사하고 있는 주요 기업

유망 약제

임상시험 프로파일 개요

부록

KSA 16.01.25

GlobalData's clinical trial report, "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Global Clinical Trials Review, H2, 2017" provides an overview of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) clinical trials scenario. This report provides top line data relating to the clinical trials on Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) to Genetic Disorders Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) to Genetic Disorders Clinical Trials 18
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials in E7 Countries by Trial Status 20
  • Clinical Trials by Phase 21
  • In Progress Trials by Phase 22
  • Clinical Trials by Trial Status 23
  • Clinical Trials by End Point Status 24
  • Subjects Recruited Over a Period of Time 25
  • Clinical Trials by Sponsor Type 26
  • Prominent Sponsors 27
  • Top Companies Participating in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials 28
  • Prominent Drugs 29
  • Clinical Trial Profile Snapshots 30

Appendix 65

  • Abbreviations 65
  • Definitions 65
  • Research Methodology 66
  • Secondary Research 66
  • About GlobalData 67
  • Contact Us 67
  • Source 67

List of Tables

List of Tables

  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 13
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 14
  • Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) to Genetic Disorders Clinical Trials, G7 Countries (%), 2017* 15
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) to Genetic Disorders Clinical Trials, E7 Countries (%), 2017* 18
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Phase, 2017* 21
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 22
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 26
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
  • Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29
Back to Top
전화 문의
F A Q